Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 76

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 76
---
 interest and our business may be adversely affected.

We use and will continue to
use registered and/or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names
may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We rely on both registration
and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced
to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the
trademark registration process, we may receive office actions from the USPTO objecting to the registration of our trademark. Although
we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO
and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications
and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks,
and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade
names, we may not be able to compete effectively and our business may be adversely affected. Additionally, we may license our trademarks
and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks
and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our
rights in or diminish the goodwill associated with our trademarks and trade names.

Moreover, any name we have
proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered
it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product
names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in
a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional
resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing
rights of third parties and be acceptable to the FDA (or the relevant administrative body in a foreign jurisdiction). Furthermore, in
many countries, owning and maintaining a trademark registration may not provide an adequate defense against